The search for biomarkers identifying key targets for the assessment of major outcomes in chronic diseases has become one of the most interesting topics of research in different areas of clinical medicine, in particular in oncology, hematology, and rheumatology. In rheumatoid arthritis (RA), one of the leading causes of disability among chronic diseases, possible biomarkers should help the rheumatologist to identify (in very early or early RA) the patients who are going to respond quickly and favorably to disease-modifying antirheumatic drugs (DMARD), those not responding to DMARD and receiving biologic therapies (among which there is great need of biomarkers to choose a “personalized” biologic agent), those not responding to any of the several biologics, and finally, in all the previous settings, those who will develop structural damage more rapidly. Currently, researchers have great interest in the field of “personalized medicine,” which should allow physicians to optimally match patient with treatment1. The ideal biomarker should be similar to glycated hemoglobin (i.e., target for HbA1c less than 7)2, which gives significant information on the metabolic status of the patient with diabetes before and after therapy, particularly the metabolic status that allows or prevents progression of vascular damage in terms of diabetes-related comorbidities such as acute myocardial infarction, stroke, or diabetic nephropathy3. RA is characterized by synovitis and joint tissue destruction, including cartilage loss and bone erosion, with variability in outcome in different patients, that is, a self-limiting disease in some, and one characterized by progressive joint destruction in others. Biomarkers could be devised to define the aggressiveness of synovitis and to monitor the structural damage, or there could be 1 ideal biomarker summarizing both aspects. The possibility of identifying the individual RA patient’s future disease severity could guide the choice of the best treatment … Address correspondence to Prof. G. Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affiliated Sciences, University of the Sacred Heart, Complesso Integrato Columbus, Via Giuseppe Moscati 31, 00168 Rome, Italy. E-mail: gf.ferraccioli{at}rm.unicatt.it